PROLIDASE LEVEL IN CORONARY ARTERY DISEASE AND ISCHEMIC MITRAL VALVE INSUFFICIENCY

Abstract

Plasma prolidase levels change as a determining factor for coronary artery disease and heart valve insufficiency. The aim of this study is to compare plasma prolidase levels in two groups with or without mitral regurgitation who underwent coronary artery bypass surgery (CABS). For this purpose, 45 patients who underwent CABS were included in the study; patients without mitral valve insufficiency who underwent CABS (25 patients) Group 1, patients with mitral valve insufficiency who underwent CABS (20 patients) Group 2. Venous blood was taken from all patients before and after CABS and their prolidase levels were measured. Preoperative and postoperative serum prolidase levels in group 1 were 1038.2 and 1289.43 U/L, respectively. In group 2, preoperative and postoperative serum prolidase levels were 1084.07 and 1337.74 U/L, respectively. A significant difference was found between preoperative and postoperative plasma prolidase levels of Group 1 and Group 2 included in the study (p<0.05). Plasma prolidase level was high in both groups. However, pre- and postoperative serum prolidase levels were found to be higher in patients with mitral valve insufficiency in Group 2. In conclusion, in this study, it was determined that the plasma prolidase level was higher in patients with mitral valve insufficiency who underwent CABS.